Study on the Incidence of Malignant Neoplasms in Patients with Parkinson's Disease and Heterozygous Mutation of the GBA Gene
Launched by AZIENDA USL REGGIO EMILIA - IRCCS · Feb 5, 2025
Trial Information
Current as of July 01, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is looking at whether people with Parkinson's disease (PD) who have a specific genetic mutation in the GBA1 gene are more likely to develop certain types of cancer, known as malignant neoplasms. Researchers want to compare this group to other Parkinson's patients without the mutation and to the general population. The study aims to better understand the relationship between this genetic mutation and cancer, which could help doctors provide better care and screening for cancer in patients with Parkinson's.
To participate in the study, individuals need to be over 18 years old and have a confirmed diagnosis of Parkinson's disease. This means they must meet specific guidelines used by medical experts. The trial is currently recruiting participants, and anyone who joins can expect to contribute to important research that might improve the understanding of cancer risks in Parkinson's patients. It's a chance to help shape future healthcare practices for individuals with this condition.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • \>18 years
- • Diagnosis of Parkinson's Disease through the United Kingdom Parkinson's Disease Society Brain Bank Diagnostic Criteria for Parkinson's Disease.
- Exclusion Criteria:
- • Uncertain diagnosis
About Azienda Usl Reggio Emilia Irccs
Azienda USL Reggio Emilia - IRCCS is a leading healthcare organization in Italy, dedicated to advancing medical research and improving patient care through innovative clinical trials. As an IRCCS (Istituto di Ricovero e Cura a Carattere Scientifico), it integrates clinical practice with scientific research, fostering collaboration among healthcare professionals, researchers, and academic institutions. The organization is committed to conducting rigorous, ethical studies that contribute to the advancement of medical knowledge and the development of new therapies, ensuring high standards of patient safety and welfare throughout the research process.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Reggio Emilia, , Italy
Milano, , Italy
Brindisi, , Italy
Trento, , Italy
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported